Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new public-private consortium (known as COMPACT) funded by the Innovative Medicines Initiative (IMI) of the EU recently launched a major new 30 million Euro project focussing on improving the delivery of biopharmaceutical drugs. The University of Oxford plays a leading
role in the consortium which also comprises experts from 14 academic institutions, two biotechnology companies and seven pharmaceutical companies. Professor Matthew Wood will lead all IMI work to develop improved methods for drug delivery to the brain. A major challenge in treating many currently incurable neurological diseases is to achieve effective drug delivery to the brain across the blood brain barrier (a natural barrier that protects the brain). This new IMI project aims to tackle this challenge within the next 5 years.

Similar stories

Louisa Zolkiewski awarded the Bruce Cattanach Prize 2022

Congratulations are in order for Louisa Zolkiewski, who completed her DPhil studies this year, on being awarded the 2022 Bruce Cattanach Prize by the Genetics Society for her DPhil thesis.

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

Winners of the DPAG Student Poster Day 2022 announced

"A Year of Progress" was held in the Sherrington Library on Wednesday 9 November 2022.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Joaquim Vieira recognised in national image competition

DPAG BHF Intermediate Research Fellow Dr Joaquim Vieira has been shortlisted for the British Heart Foundation’s annual ‘Reflections of Research’ image competition.